We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 12

Safeguarding patient-generated health information created or shared through mobile devices

  • Manatt Phelps & Phillips LLP
  • -
  • USA
  • -
  • August 3 2012

Mobile health technologies are increasingly becoming a valuable tool for improving the quality and efficiency of healthcare

U.S. Department of Health and Human Services announces details of new HIPAA Audit Program

  • Manatt Phelps & Phillips LLP
  • -
  • USA
  • -
  • November 9 2011

On November 8, 2011, the U.S. Department of Health and Human Services (“HHS”) officially posted on its website details about its new Health Insurance Portability and Accountability Act (“HIPAA”) Audit Program

GAO issues new report on 340B drug discount program

  • Manatt Phelps & Phillips LLP
  • -
  • USA
  • -
  • September 29 2011

As directed by the Patient Protection and Affordable Care Act (“PPACA”), the U.S. Government Accountability Office (“GAO”) released a report on September 23, 2011 on the federal 340B Drug Discount Program (the “340B Program”

Supreme Court strikes down Vermont prescriber data-restriction law

  • Manatt Phelps & Phillips LLP
  • -
  • USA
  • -
  • June 24 2011

On June 23, 2011, the United States Supreme Court struck down Vermont’s law restricting the sale, disclosure, and use of pharmacy records that reveal the prescribing patterns of individual physicians

Considerations for the development of accountable care organizations in New York State

  • Manatt Phelps & Phillips LLP
  • -
  • USA
  • -
  • June 21 2011

A key element of the Affordable Care Act’s health care delivery and payment reform agenda is the Medicare Shared Savings Program (MSSP

HHS proposes changes to HIPAA accounting of disclosures provision

  • Manatt Phelps & Phillips LLP
  • -
  • USA
  • -
  • May 31 2011

On May 27, 2011, the U.S. Department of Health and Human Services (“HHS”) issued a notice of proposed rulemaking (the “NPRM”) to modify the accounting of disclosures provision of the Health Information Portability and Accountability Act’s (“HIPAA”) Privacy Rule (the “Privacy Rule”

HRSA releases proposed rule implementing 340B program orphan drug exclusion

  • Manatt Phelps & Phillips LLP
  • -
  • USA
  • -
  • May 19 2011

On May 19, 2011, the Office of the Federal Register put on display a Notice of Proposed Rulemaking ("NPRM") implementing a provision of the Affordable Care Act ("ACA") that prohibits certain newly-eligible Covered Entities from receiving discounts on orphan drugs under the 340B Drug Discount Program

HHS OIG audits uncover weaknesses in health information security oversight

  • Manatt Phelps & Phillips LLP
  • -
  • USA
  • -
  • May 18 2011

On May 17, 2011, the U.S. Department of Health and Human Services’ (“HHS”) Office of the Inspector General (“OIG”) released two audit reports focused on the federal government’s health information security activities

Supreme Court rules 340b covered entities cannot sue drug manufacturers over drug pricing disputes

  • Manatt Phelps & Phillips LLP
  • -
  • USA
  • -
  • March 29 2011

On March 29, 2011, the Supreme Court, in a unanimous opinion by Justice Ruth Bader Ginsburg, ruled that safety-net health care providers, such as eligible hospitals and community health centers, enrolled in the federal 340B Drug Discount Program (the "340B Program") do not have a right to sue drug manufacturers for alleged overpricing of drugs they sell under the program

Second Circuit Court of Appeals finds Vermont prescriber data-restriction law unconstitutional

  • Manatt Phelps & Phillips LLP
  • -
  • USA
  • -
  • November 30 2010

On November 23, 2010, the U.S. Court of Appeals for the Second Circuit dealt a blow to a controversial public policy trend in which states are restricting the use of information about physician prescribing habits in pharmaceutical marketing